Aeglea Biotherapeutics Inc. (NASDAQ:AGLE)’s share price rose 8.7% during trading on Friday . The stock traded as high as $6.37 and last traded at $6.28, with a volume of 69,919 shares changing hands. The stock had previously closed at $5.78.

AGLE has been the subject of several recent analyst reports. Needham & Company LLC initiated coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 9th. They set a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research cut shares of Aeglea Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th.

The company’s market cap is $83.82 million. The company has a 50 day moving average of $5.00 and a 200 day moving average of $6.51.

Aeglea Biotherapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.03. Equities research analysts predict that Aeglea Biotherapeutics Inc. will post ($4.77) earnings per share for the current fiscal year.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.